Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Week 1 of the Virtual American Association for Cancer Research (AACR) 2021 Annual Meeting offered a variety of data on trials ranging from preclinical to phase 3 studies. In particular, Matthew J. Matasar, MD, is excited most about the presentations surrounding chromosomal instability in cancer.

Matasar, associate member of Lymphoma Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® about his hopes for future treatments coming out of the meeting.


I think AACR, for me, really brings home the breadth of scientific investigation that’ s being applied to such patients and their illnesses. And I really see the future landscape of this set of illnesses as being one in which we’re going to have more effective and less toxic treatments for our patients.

[There’s] just a tremendous breadth of scientific inquiry that’s been presented this year. I’ve been particularly interested in the story of the chromosomal instability and found the work that was presented, looking at that and documenting how this works and the clinical implications of this is really being very provocative.


Matasar MJ, Capra M, Ozcan M, et al. CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Presented at: 2021 AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract CT001.